GSK announces succession plan for cfo

Simon Dingemans joins from Goldman Sachs

Simon Dingemans has been named as chief financial officer designate and executive director of GlaxoSmithKline (GSK) from 4 January 2011. He will succeed Julian Heslop, who is to retire as chief financial officer and executive director of the company at the end of March 2011.

Dingemans joins the pharmaceutical firm from Goldman Sachs where he is currently managing director and partner. He has more than 25 years’ experience in investment banking, including most recently as leader of Goldman Sachs' European M&A business and before that as head of UK Investment Banking. During this time he has built relationships and offered strategic advice across multiple industry sectors, including pharmaceuticals and consumer healthcare.

Dingemans has worked closely with GSK for many years, most recently helping to establish ViiV Healthcare, a specialist HIV company.

Andrew Witty, chief executive of GSK, said: ‘Simon's appointment as cfo reflects the need for GSK to operate with both creativity and continued financial discipline. He will also be responsible for delivering cost savings from our global restructuring programme and implementing further measures to simplify our operational model.’

You may also like

Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
You need to be a subscriber to read this article.
Click here to find out more.
Finance

ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum

From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
Finance

Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA

SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and other complex injectable therapies to vaccines and emergency room medications
Manufacturing

Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe

After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
Finance

T-CURX acquires Pantherna Therapeutics to fast-track non-viral in vivo CAR-T pipeline

Combining transposon-based CAR-T with Pantherna's LNP and mRNA platforms, T-CURX aims to accelerate clinical trials by a year and become Europe's first biotech with both technologies in-house
Subscribe now